BioPharmSignal logoBioPharmSignal

Biotech News

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

89bio, Inc. (ETNB)89bio, Inc.Earnings

– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 topline histology data expected in 1H 2027 and in 2028, respectively; each trial designed to support accelerated approval to treat patients with metabolic dysfunction-associated steatohepatitis (MASH) – – ENTRUST Phase 3 topline data in severe

Open original release

Related news

MISTMilestone Pharmaceuticals Inc.2026-05-13 11:11 EST

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

NAMSNewAmsterdam Pharma2026-05-07 11:00 EST

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

MLYSMineralys Therapeutics2026-05-06 20:05 EST

Mineralys Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

VKTXViking Therapeutics2026-04-29 20:05 EST

Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

MLYSMineralys Therapeutics2026-03-12 20:05 EST

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

MNKDMannKind2026-05-06 20:01 EST

MannKind Reports First Quarter 2026 Financial Results and Provides Business Update

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

MISTMilestone Pharmaceuticals Inc.2026-03-20 11:55 EST

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

NAMSNewAmsterdam Pharma2026-02-18 12:01 EST

NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update

View all latest news

89bio, Inc.

89bio is a liver and metabolic disease company focused on MASH and related liver biology. Its story is driven by the possibility of creating a major liver-disease franchise.

Recent company news

ETNB89bio, Inc.2025-09-18 05:02 EST

89bio, Inc. Announces Agreement to be Acquired by Roche

ETNB89bio, Inc.2025-09-05 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ETNB89bio, Inc.2025-08-28 20:05 EST

89bio to Participate in Upcoming Investor Conferences

ETNB89bio, Inc.2025-08-07 20:06 EST

89bio Reports Second Quarter 2025 Financial Results and Corporate Updates

ETNB89bio, Inc.2025-08-04 20:05 EST

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States